赫赛汀联合多西他赛对人表皮生长因子受体-2阳性转移性乳腺癌的临床疗效

Clinical efficacy of Herceptin combined with docetaxel on human epidermal growth factor receptor-2 positive metastatic breast cancer

目的研究赫赛汀联合多西他赛对人表皮生长因子受体-2(HER-2)阳性转移性乳腺癌(PMBC)的临床疗效。方法选择2016年2月至2018年3月来开封市中心医院乳腺甲状腺科就诊的PMBC病人80例,根据随机数字表法分为两组,对照组40例采用常规治疗结合赫赛汀,研究组40例采用在对照组的基础上联合多西他赛。比较两组病人高迁移率族蛋白I-C(HMGI-C)基因和分子标志物的表达水平与血清C反应蛋白(CRP)、白细胞介素-6(IL-6)水平、并发症与随访结果情况。结果研究组总有效率为75.00%,明显优于对照组的52.50%(P<0.05);研究组病人HMGI-C基因的表达阳性率、平均标签指数(LI)值与p53阳性率均明显低于对照组(P<0.05),而雌激素受体阴性率均明显高于对照组(P<0.05);治疗后,两组病人CRP水平明显降低,IL-6水平明显上升(P<0.05),但研究组病人CRP、IL-2水平均明显优于对照组(P<0.05);研究组、对照组病人总并发症发生率分别为10.00%、5.00%(χ^2=0.721,P=0.396),随访期间,研究组、对照组病人死亡率为40%、55%(χ^2=1.782,P=0.182)。结论采用赫赛汀联合多西他赛可以明显提高HER-2 PMBC病人的临床疗效,抑制癌细胞发展,降低并发症发生率,改善病人预后。

Objective To study the clinical efficacy of Herceptin combined with docetaxel on human epidermal growth factor recep-tor-2(HER2)positive metastatic breast cancer(PMBC).Methods Eighty patients with PMBC who came to the Department ofBreast and Thyroid of Kaifeng Central Hospital from February 2016 to March 2018 were selected and assigned into two groups ac-cording to the random number table method.40 patients in the control group were treated with conventional treatment combinedwith Herceptin,while 40 patients in the study group were combined with docetaxel on the basis of the control group.The expressionlevels of high mobility group protein I-C(HMGI-C)gene and molecular markers and serum C-reactive protein(CRP),interleukin-6(IL-6)levels,complications and follow-up results were compared between the two groups.ResultsThe total effective rate of thestudy group was 75.00%,which was significantly better than 52.50%of the control group(P<0.05).The positive rate,mean label-ing index(LI)and p53 positive rate of HMGI-C gene in the study group were significantly lower than those in the control group(P<0.05),while the estrogen receptor negative rate in the study group was significantly higher than that in the control group(P<0.05).After treatment,CRP levels were significantly decreased,and IL-6 levels were significantly increased in the two groups(P<0.05),but the CRP and IL-2 levels in the study group were significantly better than those in the control group(P<0.05).The totalcomplication rate of patients in the study group and the control group was 10.00%and 5.00%,respectively(χ^2=0.721,P=0.396).During the follow-up period,the mortality of the study group and the control group was 40%and 55%,respectively(χ^2=1.782,P=0.182).ConclusionThe combination of Herceptin and docetaxel can significantly improve the clinical efficacy of HER-2 PMBCpatients,inhibit the development of cancer cells,reduce the incidence of complications,and improve the prognosis of patients.